$14.49-0.37 (-2.49%)
Dr.
Dr. Reddy's Laboratories Limited in the Healthcare sector is trading at $14.49 with a market capitalization of $10.8B. Wall Street consensus targets $14.26 (5 analysts), implying a -1.6% move over the next 12 months. The stock is currently 8% below its 52-week high of $15.67, remaining 4.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $75.16Bβ | $87.27Bβ | $88.05Bβ | $85.45Bβ | $85.06B |
| Gross Profit | $43.03Bβ | $46.81Bβ | $48.14Bβ | $48.63Bβ | $56.56B |
| Operating Income | $829.00Mβ | $14.33Bβ | $17.87Bβ | $16.84Bβ | $16.20B |
| Net Income | $2.21Bβ | $12.10Bβ | $14.37Bβ | $14.18Bβ | $15.93B |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingr...
Asian equities traded in the US as American depositary receipts were trading higher Monday morning,
Asian equities traded in the US as American depositary receipts were lower Thursday morning, declini
Asian equities traded in the US as American depositary receipts fell Tuesday morning, tumbling 3.1%
Asian equities traded in the US as American depositary receipts opened the week slightly higher Mond
Asian equities traded in the US as American depositary receipts ended the shortened trading week sha